

March 2, 2015



Actinium to Present at the 27th Annual ROTH Conference March 11th

NEW YORK, NY -- (Marketwired) -- 03/02/15 -- [Actinium Pharmaceuticals, Inc.](#) (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 at 10:00 a.m. The conference will take place from March 8-11, 2015 at the Ritz-Carlton Laguna Niguel, CA.

Sandesh Seth, Executive Chairman, will provide an overview of the company and recent activities. You can view the presentation webcast at <http://www.actiniumpharma.com/investors/events/>.

This conference is one of the largest of its kind in the U.S. Following the success of previous years' events, the ROTH Conference, with close to 500 participating companies and over 3,000 attendees, will feature presentations from hundreds of public and private companies in a variety of sectors. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.

Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at (646) 840-5442 or esmith@actiniumpharma.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc. Evan Smith, CFA VP Investor Relations and Finance (646 esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals